Mirum Pharmaceuticals vs Pharming
MIRM and PHAR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MIRM and PHAR compare
Mirum Pharmaceuticals grew revenue faster over the last twelve months (44.0% versus 26.6% for Pharming).
Pharming keeps more of each dollar of sales as profit, with a net margin of 0.76% compared with −139% at Mirum Pharmaceuticals.
Pharming scores higher on the StockData Score (8 against 5 for Mirum Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MIRM | PHAR |
|---|---|---|
| Size and price | ||
| Market cap | $6.1B | – |
| Share price | $94.61 | $13.40 |
| Change, 1 year | 35.7% | −23.6% |
| Change, 5 years | 503% | 55.5% |
| Beta (5Y) | 0.64 | 0.56 |
| Employees | 372 | 50K |
| StockData Score | ||
| Total score | 5 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 1 | 1 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.9× | – |
| FCF yield | −3.7% | – |
| Growth | ||
| Revenue growth (TTM) | 44.0% (better) | 26.6% |
| Revenue growth, 5Y average | – | 12.1% |
| EPS growth, 5Y average | – | −40.8% |
| Profitability | ||
| Gross margin | – | 87.9% |
| Operating margin | −135% | 6.9% (better) |
| Net margin | −139% | 0.76% (better) |
| FCF margin | −37.0% | 14.3% (better) |
| Return on equity | −703% | – |
| Financial health | ||
| Interest coverage | −62.1× | 132× (better) |
| Current ratio | 2.86 (better) | 2.59 |
| Altman Z-score | −0.12 | – |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 110% | 0.32% |
| Held by insiders | 9.2% | 0.00% |
| Insider net buying, 12 months | −$31.5M | – |
| Short interest, % of float | 11.1% | – |
Go deeper
- MIRM stock overview
- MIRM income statement
- MIRM valuation and score
- PHAR stock overview
- PHAR income statement
- PHAR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.